Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Axogen, Inc.
Report date July 18, 2022 · Filed July 20, 2022
Section 16 reporting ended · disclosed 2022-07-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 16,081 |
Ending reported balance
After 2022-07-19 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-07-18 · Grant · Acquired 4,408 · Balance 17,206 F1: This reflects the number of shares that vested as of July 18, 2022 upon the attainment of certain performance criteria. Row 2 · 2022-07-19 · Disposition to issuer · Disposed 1,125 · Balance 16,081 F2: The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on July 19, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: This reflects the number of shares that vested as of July 18, 2022 upon the attainment of certain performance criteria.
F2: The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on July 19, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 19, 2022 Filed Jul 20, 2022 20:07 UTC | Axogen, Inc. AXGN · Entity 4297 | Disposition to issuerCommon Stock | 1,125 | $8.40 | $9,450.00 |
DisclosureSEC source: 0000805928-22-000096 · wf-form4_165834762985277.xml · nonDerivative · entry 2 Sandberg Eric · CIK 0001764446 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,081 F2 · shares: The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on July 19, 2022. Read SEC document |
| July 18, 2022 Filed Jul 20, 2022 20:07 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 4,408 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000096 · wf-form4_165834762985277.xml · nonDerivative · entry 1 Sandberg Eric · CIK 0001764446 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,206 F1 · shares: This reflects the number of shares that vested as of July 18, 2022 upon the attainment of certain performance criteria. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:10 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantEmployee Stock Option (right to purchase) · Derivative | 60,576 | $0.00 Strike: $10.25 | $0.00 |
DisclosureSEC source: 0000805928-22-000033 · wf-form4_164763418939739.xml · derivative · entry 5 Sandberg Eric · CIK 0001764446 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,576 Underlying: Common Stock · 60,576 shares Expires 2032-03-16 F6 · derivative.exercise_price: The exercise price of $10.25 represents a 25% premium over the fair market value of Axogen common stock on the date of the grant. F7 · derivative.exercise_date: All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2026 (4 years from the option grant date) based upon a vesting schedule whereby 25% of the aggregate shares vest on March 16, 2023 and on each anniversary thereafter. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:10 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 62,910 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000033 · wf-form4_164763418939739.xml · derivative · entry 4 Sandberg Eric · CIK 0001764446 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,910 Underlying: Common Stock · 62,910 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F5 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F5 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:10 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000033 · wf-form4_164763418939739.xml · derivative · entry 3 Sandberg Eric · CIK 0001764446 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F4 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F4 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:10 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 1,512 | $7.97 | $12,050.64 |
DisclosureSEC source: 0000805928-22-000033 · wf-form4_164763418939739.xml · nonDerivative · entry 2 Sandberg Eric · CIK 0001764446 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,798 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:10 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000033 · wf-form4_164763418939739.xml · nonDerivative · entry 1 Sandberg Eric · CIK 0001764446 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,310 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that became vested as of March 16, 2022. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:12 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 762 | $8.42 | $6,416.04 |
DisclosureSEC source: 0000805928-22-000014 · wf-form4_164513232552416.xml · nonDerivative · entry 2 Sandberg Eric · CIK 0001764446 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,310 F2 · shares: The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on February 15, 2022. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:12 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 2,531 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000014 · wf-form4_164513232552416.xml · nonDerivative · entry 1 Sandberg Eric · CIK 0001764446 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,072 F1 · shares: This reflects the number of shares that became vested as of February 15, 2022 upon the attainment of certain performance criteria. Read SEC document |
| July 20, 2021 Filed Jul 21, 2021 20:14 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 1,090 | $19.20 | $20,928.00 |
DisclosureSEC source: 0000805928-21-000145 · wf-form4_162689846251349.xml · nonDerivative · entry 2 Sandberg Eric · CIK 0001764446 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,541 F2 · shares: The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on July 19, 2021. Read SEC document |
| July 19, 2021 Filed Jul 21, 2021 20:14 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 4,408 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000145 · wf-form4_162689846251349.xml · nonDerivative · entry 1 Sandberg Eric · CIK 0001764446 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,631 F1 · shares: This reflects the number of shares that became vested as of July 19, 2021 upon the attainment of certain performance criteria. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 21:53 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 11,800 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000059 · wf-form4_161610441718155.xml · derivative · entry 2 Sandberg Eric · CIK 0001764446 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,800 Underlying: Common Stock · 11,800 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F3 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F3 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 21:53 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantEmployee Stock Option (right to purchase) · Derivative | 23,500 | $0.00 Strike: $20.91 | $0.00 |
DisclosureSEC source: 0000805928-21-000059 · wf-form4_161610441718155.xml · derivative · entry 1 Sandberg Eric · CIK 0001764446 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,500 Underlying: Common Stock · 23,500 shares Expires 2031-03-16 F1 · derivative.exercise_date: All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2025 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 22:25 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 903 | $18.70 | $16,886.10 |
DisclosureSEC source: 0000805928-21-000026 · wf-form4_161368713357992.xml · nonDerivative · entry 2 Sandberg Eric · CIK 0001764446 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,223 F2 · shares: The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on February 16, 2021. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 22:25 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 2,531 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000026 · wf-form4_161368713357992.xml · nonDerivative · entry 1 Sandberg Eric · CIK 0001764446 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,126 F1 · shares: This reflects the number of shares that became vested as of February 16, 2021 upon the attainment of certain performance criteria. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 21:12 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-003908 · edgar.xml · derivative · entry 2 Sandberg Eric · CIK 0001764446 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F3 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F3 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 21:12 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantEmployee Stock Option (right to purchase) · Derivative | 24,000 | $0.00 Strike: $8.61 | $0.00 |
DisclosureSEC source: 0001179110-20-003908 · edgar.xml · derivative · entry 1 Sandberg Eric · CIK 0001764446 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2030-03-16 F1 · derivative.exercise_date: All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2024 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 18:19 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 936 | $14.68 | $13,740.48 |
DisclosureSEC source: 0001179110-20-001945 · edgar.xml · nonDerivative · entry 2 Sandberg Eric · CIK 0001764446 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,595 F2 · shares: The reported shares were withheld to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on February 18, 2020. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 18:19 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 2,531 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001945 · edgar.xml · nonDerivative · entry 1 Sandberg Eric · CIK 0001764446 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,531 F1 · shares: This reflects the number of shares that became vested as of February 18, 2020 upon the attainment of certain performance criteria. F1 · price: This reflects the number of shares that became vested as of February 18, 2020 upon the attainment of certain performance criteria. Read SEC document |
| January 21, 2019 Filed Jan 23, 2019 02:07 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantEmployee Stock Option (right to purchase) · Derivative | 45,000 | $0.00 Strike: $16.17 | $0.00 |
DisclosureSEC source: 0001179110-19-000862 · edgar.xml · derivative · entry 1 Sandberg Eric · CIK 0001764446 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2029-01-21 F1 · derivative.exercise_date: All shares of AxoGen, Inc. common stock underlying the employee stock option will be fully vested on January 21, 2023 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on January 21, 2021 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.